The FDA approved a new monthly paliperidone palmitate (Erzofri) extended-release injectable suspension for treating schizophrenia in adults, Luye Pharma announced. An atypical antipsychotic ...

Paliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.

PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale ...

Paliperidone palmitate once every 6 months (or PP6M) is the first LAI with a substantially longer dosing interval of every 6 months (twice yearly).

The paliperidone ER study by Canuso et al and the risperidone study by Potkin et al evaluated monotherapy for only 2 weeks, followed by a 4-week additive therapy phase during which additional ...

Janssen Inc v Teva Canada Ltd, 2020 FC 593 (Teva Paliperidone; previously reported): The Court found certain claims of the 335 patent valid and infringed by Teva (Teva’s appeal was heard ...

How to Take Paliperidone Palmitrate and it's Dose Written by - Dhanalakshmi Chinnuswamy, Diploma in Pharmacy, MBA (Healthcare) Medically Checked by - S. Hemamalini, B. Pharm ...

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder ...

Weight changes with paliperidone ER and risperidone were similar (paliperidone ER vs risperidone 2–4 mg/day, p = 0.489; paliperidone ER vs risperidone 4–6 mg/day, p = 0.236).